Valneva (NASDAQ:VALN) Shares Down 3.9%

Valneva SE (NASDAQ:VALN - Get Free Report) shares were down 3.9% during trading on Friday . The stock traded as low as $7.81 and last traded at $7.81. Approximately 1,758 shares were traded during trading, a decline of 81% from the average daily volume of 9,062 shares. The stock had previously closed at $8.13.

Wall Street Analyst Weigh In

Several research analysts have commented on VALN shares. Guggenheim dropped their price objective on shares of Valneva from $18.00 to $17.00 and set a "buy" rating for the company in a report on Friday, March 22nd. HC Wainwright reissued a "buy" rating and issued a $26.00 price objective on shares of Valneva in a research report on Thursday, March 21st.

Valneva Trading Down 6.3 %

The firm has a market capitalization of $529.29 million, a PE ratio of -4.82 and a beta of 2.25. The stock's 50-day moving average price is $7.67 and its 200 day moving average price is $9.62. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37.

Valneva (NASDAQ:VALN - Get Free Report) last issued its earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of $0.20 by ($0.70). The company had revenue of $45.12 million for the quarter, compared to analysts' expectations of $45.06 million. Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. On average, sell-side analysts expect that Valneva SE will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG bought a new position in shares of Valneva during the second quarter valued at approximately $31,000. Jane Street Group LLC boosted its stake in shares of Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock valued at $569,000 after purchasing an additional 7,664 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Valneva during the first quarter valued at approximately $858,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.